Abbott Laboratories (NYSE:ABT – Get Free Report) has received an average rating of “Moderate Buy” from the twelve brokerages that are presently covering the stock, MarketBeat Ratings reports. Three analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $121.31.
ABT has been the topic of a number of analyst reports. Raymond James increased their price target on shares of Abbott Laboratories from $124.00 to $127.00 and gave the company an “outperform” rating in a research report on Thursday, January 25th. Royal Bank of Canada decreased their price target on shares of Abbott Laboratories from $128.00 to $125.00 and set an “outperform” rating for the company in a report on Thursday. TheStreet upgraded Abbott Laboratories from a “c+” rating to a “b-” rating in a report on Thursday, December 21st. Citigroup increased their price target on Abbott Laboratories from $126.00 to $128.00 and gave the stock a “buy” rating in a report on Wednesday, April 3rd. Finally, Barclays boosted their price objective on Abbott Laboratories from $133.00 to $141.00 and gave the company an “overweight” rating in a research report on Friday, January 26th.
Get Our Latest Analysis on Abbott Laboratories
Insider Activity at Abbott Laboratories
Institutional Investors Weigh In On Abbott Laboratories
Large investors have recently added to or reduced their stakes in the business. Alliance Wealth Advisors LLC UT raised its position in shares of Abbott Laboratories by 0.4% in the fourth quarter. Alliance Wealth Advisors LLC UT now owns 25,085 shares of the healthcare product maker’s stock valued at $2,761,000 after purchasing an additional 92 shares during the period. Rappaport Reiches Capital Management LLC lifted its position in Abbott Laboratories by 0.8% during the fourth quarter. Rappaport Reiches Capital Management LLC now owns 12,287 shares of the healthcare product maker’s stock worth $1,352,000 after acquiring an additional 94 shares during the last quarter. Avion Wealth boosted its holdings in shares of Abbott Laboratories by 19.4% during the fourth quarter. Avion Wealth now owns 591 shares of the healthcare product maker’s stock worth $65,000 after acquiring an additional 96 shares during the period. Patriot Investment Management Group Inc. increased its stake in shares of Abbott Laboratories by 3.1% during the fourth quarter. Patriot Investment Management Group Inc. now owns 3,236 shares of the healthcare product maker’s stock worth $356,000 after purchasing an additional 96 shares during the period. Finally, Wynn Capital LLC boosted its stake in Abbott Laboratories by 2.9% in the 1st quarter. Wynn Capital LLC now owns 3,427 shares of the healthcare product maker’s stock valued at $390,000 after purchasing an additional 98 shares during the period. Institutional investors own 75.18% of the company’s stock.
Abbott Laboratories Stock Performance
Shares of NYSE:ABT opened at $105.27 on Friday. The company has a current ratio of 1.64, a quick ratio of 1.16 and a debt-to-equity ratio of 0.35. Abbott Laboratories has a 1-year low of $89.67 and a 1-year high of $121.64. The stock has a market capitalization of $182.66 billion, a P/E ratio of 32.29, a P/E/G ratio of 2.63 and a beta of 0.74. The business has a 50-day moving average price of $114.28 and a two-hundred day moving average price of $107.57.
Abbott Laboratories (NYSE:ABT – Get Free Report) last released its earnings results on Wednesday, April 17th. The healthcare product maker reported $0.98 EPS for the quarter, topping analysts’ consensus estimates of $0.96 by $0.02. Abbott Laboratories had a net margin of 14.27% and a return on equity of 20.65%. The firm had revenue of $9.96 billion during the quarter, compared to analyst estimates of $9.88 billion. During the same quarter in the previous year, the business earned $1.03 EPS. The business’s quarterly revenue was up 2.2% compared to the same quarter last year. Equities analysts predict that Abbott Laboratories will post 4.62 earnings per share for the current year.
Abbott Laboratories Dividend Announcement
The firm also recently declared a quarterly dividend, which will be paid on Wednesday, May 15th. Shareholders of record on Monday, April 15th will be paid a $0.55 dividend. The ex-dividend date of this dividend is Friday, April 12th. This represents a $2.20 annualized dividend and a yield of 2.09%. Abbott Laboratories’s payout ratio is currently 67.48%.
About Abbott Laboratories
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.
Featured Articles
- Five stocks we like better than Abbott Laboratories
- 3 Monster Growth Stocks to Buy Now
- Comprehensive PepsiCo Stock Analysis
- What Makes a Stock a Good Dividend Stock?
- CSX Co.: The Railroad Powering Ahead with an Earnings Beat
- Low PE Growth Stocks: Unlocking Investment Opportunities
- 3 Steel Stocks Could Soar on New China Tariffs
Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.